Biotech Values

[rwwine]

Assuming Sanofi launches a generic Lovenox (sL) of their own and dividing up the estimated total sales revenue equally among 4 (Branded Lovenox, sL, mL, & now aL), I estimate MNTA to generate $11.7 Million/quarter with an EPS of -$0.23

**Note - NVS if I recall, will now pay back MNTA some of the original R&D cost in MNTA's efforts to develop mL. I would imagine this is a one time payment to MNTA.